Aug 7 (Reuters) - Eli Lilly LLY.N CEO David Ricks said the U.S. pharmaceutical market's structure needs "urgent reform" before any meaningful changes to drug pricing can be implemented.
His comments come after Lilly, along with 16 other major drugmakers, received a letter from President Donald Trump on July 31, urging them to cut U.S. drug prices to match those paid by other wealthy nations.
On call with analysts on Thursday, Ricks said he backed the Trump administration's push for more equitable global sharing of medical research costs, but warned that directly comparing the different pricing systems could be "inaccurate and misleading."